Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Accumulating evidence suggests that mesenchymal stem cells (MSCs) are recruited to the tumor microenvironment; however, controversy exists regarding their role in solid tumors. In this study, we identified and confirmed the presence of carcinoma-associated MSCs (CA-MSCs) in the majority of human ovarian tumor samples that we analyzed. These CA-MSCs had a normal morphologic appearance, a normal karyotype, and were nontumorigenic. CA-MSCs were multipotent with capacity for differentiating into adipose, cartilage, and bone. When combined with tumor cells in vivo, CA-MSCs promoted tumor growth more effectively than did control MSCs. In vitro and in vivo studies suggested that CA-MSCs promoted tumor growth by increasing the number of cancer stem cells. Although CA-MSCs expressed traditional MSCs markers, they had an expression profile distinct from that of MSCs from healthy individuals, including increased expression of BMP2, BMP4, and BMP6. Importantly, BMP2 treatment in vitro mimicked the effects of CA-MSCs on cancer stem cells, while inhibiting BMP signaling in vitro and in vivo partly abrogated MSC-promoted tumor growth. Taken together, our data suggest that MSCs in the ovarian tumor microenvironment have an expression profile that promotes tumorigenesis and that BMP inhibition may be an effective therapeutic approach for ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The tumor-supporting properties of MSC (immunomodulation, angiogenesis, cell survival or migration) often seem to be enhanced in tumor-derived MSC populations [45, 74, 75].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Chamberlain, G., Fox, J., Ashton, B., & Middleton, J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0197 · Cited by 2,381
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Efficient tumour formation by single human melanoma cells
Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008) · Nature · doi:10.1038/nature07567 · Cited by 1,796
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166
Role of tumor-associated macrophages in tumor progression and invasion
Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9001-7 · Cited by 888
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks
Liu, S., Ginestier, C., Ou, S. J., Clouthier, S. G., Patel, S. H., Monville, F., Korkaya, H., Heath, A., Dutcher, J., Kleer, C. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0538 · Cited by 611
Research works printed but not linked: 2
- 10.1634/stemcells.2008-0037 · DOI
- Ye, 2007, Histol Histopathol., 22, 1129
Cited by
Items 201–300 of 410
BMP2 as a promising anticancer approach: functions and molecular mechanisms
Li, T., Lai, Y.-W., Han, X., Niu, X., & Zhang, P.-X. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01298-4 · Cited by 29
“In a human ovarian carcinoma model in vitro, BMP2 augmented the effects of CA-MSCs on tumorigenesis and cancer stem cells [176].”
BackgroundCold atmospheric plasma: Novel opportunities for tumor microenvironment targeting
Dai, X., & Zhu, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5491 · Cited by 29
Hazrati, A., Malekpour, K., Mirsanei, Z., Khosrojerdi, A., Rahmani-Kukia, N., Heidari, N., Abbasi, A., & Soudi, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1280601 · Cited by 29
TA-MSCs, TA-MSCs-EVs, MIF: their crosstalk in immunosuppressive tumor microenvironment
Zhang, Z., Zhou, X., Guo, J. J., Zhang, F., Qian, Y., Wang, G., Duan, M., Wang, Y., Zhao, H., Yang, Z., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03528-y · Cited by 28
“Human OC-MSCs OC Promotion In vitro and vivo [87, 96, 97, 174]”
BackgroundHulou, M. M., Cho, C., Chiocca, E. A., & Bjerkvig, R. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00011-6 · Cited by 28
Putative mesenchymal stem cells isolated from adult human ovaries
Štimpfel, M., Cerkovnik, P., Novaković, S., Maver, A., & Virant‐Klun, I. (2014) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-014-0254-8 · Cited by 28
Ávila-Ibarra, L. R., Mora‐García, M. D. L., García‐Rocha, R., Hernández‐Montes, J., Weiss‐Steider, B., Montesinos, J. J., Soberon, M. L., García‐López, P., López, C. A. D., Torres‐Pineda, D. B., et al. (2019) · Stem Cells and Development · doi:10.1089/scd.2018.0183 · Cited by 28
Horst, E. N., Bregenzer, M. E., Mehta, P., Snyder, C. S., Repetto, T., Yang‐Hartwich, Y., & Mehta, G. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.041 · Cited by 27
Adipose-derived stem cells in ovarian cancer progression, metastasis, and chemoresistance
Zhang, W., Torres-Rojas, C., Yue, J., & Zhu, B. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211023846 · Cited by 27
“However, CA-MSCs promoted tumor growth more effectively than normal ADSCs by increasing CSCs and expressed higher BMPs.50 RNA-seq analysis of omental ADSCs and ovarian CA-MSCs found that the latter one occur from OC-mediated reprograming of ADSCs from local normal tissue.”
BackgroundInfluentialStorti, G., Scioli, M. G., Kim, B., Terriaca, S., Fiorelli, E., Orlandi, A., & Cervelli, V. (2021) · Cells · doi:10.3390/cells10082117 · Cited by 26
“Ovarian cancer cell secretory activity can transform the ADSCs in cancer-associated ADSCs (ca-ADSCs) with a paracrine mechanism [66].”
BackgroundWaters, J. A., Robinson, M., Lujano-Olazaba, O., Lucht, C., Gilbert, S. F., & House, C. D. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2613 · Cited by 25
“…mesenchymal stem cells demonstrated that cancer-associated mesenchymal stem cells increase cancer stem cell capacity, which we did not observe with preadipocytes, and suggests that these two populations of adipocyte precursor cells promote tumorigenesis via distinct mechanisms (53).”
BackgroundStromal-Modulated Epithelial-to-Mesenchymal Transition in Cancer Cells
Atiya, H. I., Gorecki, G., Garcia, G. L., Frisbie, L. G., Baruwal, R., & Coffman, L. G. (2023) · Biomolecules · doi:10.3390/biom13111604 · Cited by 25
“In ovarian cancer, CA-MSCs have been associated with protumorogenic behavior and chemotherapy resistance [62,63].”
BackgroundHofer, E. L., Labovsky, V., Russa, V. L., Vallone, V. B. F., Honegger, A. E., Belloc, C. G., Wen, H. C., Bordenave, R. H., Bullorsky, E. O., Feldman, L. J., et al. (2009) · Stem Cells and Development · doi:10.1089/scd.2008.0375 · Cited by 25
Nieß, H., Thomas, M. N., Schiergens, T. S., Kleespies, A., Jauch, K., Bruns, C. J., Werner, J., Nelson, P. J., & Angele, M. K. (2016) · Innovative Surgical Sciences · doi:10.1515/iss-2016-0005 · Cited by 25
“Similar results were observed in a model of ovarian cancer, where MSCs raised the CSC count through BMP2 signaling [70].”
ResultXu, R., Zhao, X., Zhao, Y., Chen, B., Sun, L., Xu, C., Shen, B., Wang, M., Xu, W., & Zhu, W. (2017) · Cell Proliferation · doi:10.1111/cpr.12399 · Cited by 25
Zhang, T., Xu, J., Deng, S., Zhou, F., Li, J., Zhang, L., Li, L., Wang, Q., & Li, F. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196351 · Cited by 25
Portier, L., Desterke, C., Chaker, D., Oudrhiri, N., Asgarova, A., Dkhissi, F., Turhan, A. G., Griscelli, A. B., & Griscelli, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031227 · Cited by 25
The Role of Bone Morphogenetic Protein 4 in Ovarian Function and Diseases
Yang, D., Yang, X., Dai, F., Wang, Y., Yang, Y., Hu, M. S., & Cheng, Y. (2021) · Reproductive Sciences · doi:10.1007/s43032-021-00600-8 · Cited by 25
Axemaker, H., Plesselova, S., Calar, K., Jorgensen, M. M., Wollman, J. W., & de la Puente, P. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119801 · Cited by 24
Glioma-associated mesenchymal stem cells
Kang, Q., Wang, J., Chen, S., Song, S.-R., & Yu, S. (2023) · Brain · doi:10.1093/brain/awad360 · Cited by 23
CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary
Bai, S., Zhu, W., Coffman, L. G., Vlad, A., Schwartz, L. E., Elishaev, E., Drapkin, R., & Buckanovich, R. J. (2019) · Cancers · doi:10.3390/cancers11111710 · Cited by 23
“While TCGA samples are enriched for cancer cells, they still represent whole tumor expression and cannot directly be linked to CD105 function on tumor cells as CD105 is also expressed on tumor endothelial cells and cancer-associated mesenchymal stem cells [30,42].”
BackgroundSelf-citationNaora, H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00018 · Cited by 22
Ananthula, S., Sinha, A., Gassim, M. E., Batth, S., Marshall, G. D., Gardner, L. H., Shimizu, Y., & ElShamy, W. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8029 · Cited by 22
“TICs and EMT enhance tumor progression [43], drug-/radio-resistance and post-treatment relapse [44] in breast cancers [45–47].”
BackgroundMelanoma educates mesenchymal stromal cells towards vasculogenic mimicry
Вартанян, А. А., Karshieva, S. S., Домбровский, В. С., & Belyavsky, A. V. (2016) · Oncology Letters · doi:10.3892/ol.2016.4523 · Cited by 22
Zhang, S., Zhao, C., Liu, S., Wang, Y., Zhao, Y., Guan, W., & Zhu, Z. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9172 · Cited by 21
“Among the various types of MSCs, bone marrow MSCs (BM-MSCs), which are pluripotent progenitor cells, are deemed to be able to influence natural immune function (9), the inhibition of local inflammatory responses (10) and sepsis (11,12).”
Retinoic Acid Inhibits Tumor-Associated Mesenchymal Stromal Cell Transformation in Melanoma
Lou, Q., Zhao, M., Xu, Q., Xie, S., Liang, Y., Chen, J., Yuan, L., Wang, L., Jiang, L., Mou, L., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.658757 · Cited by 21
Razmkhah, M., Abtahi, S., & Ghaderi, A. A. (2018) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x13666180816114809 · Cited by 21
Therapeutic strategies for targeting the ovarian tumor stroma
Ko, S. Y., & Naora, H. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i6.194 · Cited by 21
Mendoza-Martinez, A. K., Loessner, D., Mata, Á., & Azevedo, H. S. (2021) · Cancers · doi:10.3390/cancers13225745 · Cited by 21
“The upregulation of TGF-β i CA-MSCs increases the number of CSCs nd chemoresistance [30,31].”
BackgroundEpidemiology of Ovarian Cancer: Risk Factors and Prevention
Sumanasekera, W. K. (2018) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2018.11.002076 · Cited by 20
The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype
Jing, Y., Liang, W., Zhang, L., Tang, J., & Huang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817971 · Cited by 20
“BMP2 can significantly increase the number of CSCs in primary ovarian tumor cells and ovarian cancer cell lines (10).”
BackgroundInfluentialLv, C., Dai, H., Sun, M., Zhao, H., Wu, K., Zhu, J. J., Wang, Y., Cao, X., Xia, Z., & Xue, C. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000325 · Cited by 20
Ryan, D., Sinha, A., Bogan, D. R., Davies, J. D., Koziol, J., & ElShamy, W. M. (2017) · Oncotarget · doi:10.18632/oncotarget.20892 · Cited by 20
“Macrophages polarization into M1-macrophages was accomplished by incubation with 100ng/ml of lipopolysaccharide (LPS, Sigma), and into M2 by incubation with 20ng/ml of interleukine-4 (IL-4, R&D Systems, Minneapolis, MN, USA) for 24h in accordance with previous protocol [73].”
MethodRethinking ovarian cancer III: the past decade and future directions
Balkwill, F. R., Laumont, C. M., Burdett, N. L., Saux, O. L., Garsed, D. W., Grither, W. R., Nijhuis, A. M., Recouvreux, M. S., Kang, Z., Zhang, R., et al. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00916-0 · Cited by 20
“CA-MSCs are multipotent cells that can differentiate into CAFs or adipocytes 108 .”
Self-citationVerardo, R., Piazza, S., Klarić, E., Ciani, Y., Bussadori, G., Marzinotto, S., Mariuzzi, L., Cesselli, D., Beltrami, A. P., Mano, M., et al. (2014) · Stem Cells · doi:10.1002/stem.1791 · Cited by 19
Chang, W. H., & Lai, A. G. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.008 · Cited by 19
Epigenetic Mechanisms beyond Tumour–Stroma Crosstalk
Gagliano, T., & Brancolini, C. (2021) · Cancers · doi:10.3390/cancers13040914 · Cited by 19
“In the 2011, a critical stromal stem cell, the carcinoma-associated mesenchymal stem/stromal cell (CA-MSC) was identified [33].”
BackgroundZaman, W. S. W. K., Nurul, A. A., & Nordin, F. (2021) · Biomedicines · doi:10.3390/biomedicines9091245 · Cited by 18
“In ovarian cancer, carcinoma-associated MSCs (CA-MSCs) promoted tumour growth by increasing the number of CSCs via BMP2 and BMP4 [46].”
BackgroundRole of cancer-educated mesenchymal stromal cells on tumor progression
Liu, T., Guo, S., Ji, Y., & Zhu, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115405 · Cited by 18
Mesenchymal Stem Cells: Miraculous Healers or Dormant Killers?
Ghaderi, A. A., & Abtahi, S. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9824-y · Cited by 18
“Induction of stemness in cancer cells by MSCs has been shown in ovarian [60, 68], breast [64, 67], gastric [69], colon”
Li, W., Yang, J. Y., Zheng, P., Li, H., & Zhao, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.723707 · Cited by 18
“Ovarian carcinoma BMP2, BMP4, BMP6 BMP (32)”
InfluentialPancreatic Tumor‐Targeting Stemsome Therapeutics
Park, J., Park, J. Y., Jeong, Y., Park, J., Park, Y. H., Kim, S., & Khang, D. (2023) · Advanced Materials · doi:10.1002/adma.202300934 · Cited by 18
Taheri, M., Tehrani, H. A., Dehghani, S., Rajabzadeh, A., Alibolandi, M., Zamani, N., Arefian, E., & Ramezani, M. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.01.004 · Cited by 18
Calpe, S., Correia, A. C. P., Sancho‐Serra, M. D. C., & Krishnadath, K. K. (2016) · mAbs · doi:10.1080/19420862.2016.1158380 · Cited by 18
“When inhibiting BMP signaling in vitro and in vivo mesenchymal stem cell-promoted tumor growth is abrogated.(12) These examples providence evidence for future therapeutic applications of C8C8.”
BackgroundIn vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow
Wang, G., Shen, G., & Yin, T. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.11.014 · Cited by 18
The Current Status of Cell-Based Therapies for Primary Knee Osteoarthritis
Vakharia, R. M., Roche, M. W., Alcerro, J. C., & Lavernia, C. J. (2019) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2019.06.001 · Cited by 17
Anti-Inflammatory Effects of M-MSCs in DNCB-Induced Atopic Dermatitis Mice
Ryu, B., Baek, J., Kim, H.-N., Lee, J.-H., Kim, J., Jeong, Y.-H., Lee, S., Kang, K.-R., Oh, M.-S., Kim, E., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8100439 · Cited by 17
“With regard to the regulation of inflammation in AD lesions, MSCs would be worthwhile to develop as a treatment since MSCs can affect natural immune function regulation [35,36] and local inflammatory response induction [36,37].”
BackgroundMesenchymal stem cells in cancer therapy; the art of harnessing a foe to a friend.
Karimi‐Shahri, M., Javid, H., Mashhad, A. S., Yazdani, S., & Hashemy, S. I. (2021) · PubMed Central · doi:10.22038/ijbms.2021.58227.12934 · Cited by 17
“Aside from chemokines, the secretion of bone morphogenetic proteins (BMPs) and several microRNAs such as mir-199 and mir-214 has been attributed to MSCs as a mechanism to sustain CSCs in TME (9, 69).”
BackgroundChauhan, A., Agarwal, S., Masih, M., & Gautam, P. K. (2023) · Immunological Investigations · doi:10.1080/08820139.2023.2249025 · Cited by 17
Hypermethylation Leads to Bone Morphogenetic Protein 6 Downregulation in Hepatocellular Carcinoma
He, Y., Cui, Y., Xu, B., Gu, J. F., Wang, W. T., & Luo, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087994 · Cited by 17
Burgos-Ojeda, D., McLean, K., Bai, S., Pulaski, H. L., Gong, Y., da Silva, I. S., Skorecki, K. L., Tzukerman, M., & Buckanovich, R. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2845 · Cited by 17
“It is possible that the addition of other pro-angiogenic cells such MSCs (33) or tumor-associated myeloid cells (34) could further increase the percentage of human vessels.”
BackgroundSelf-citationOseto, K., Suzumori, N., Nishikawa, R., Nishikawa, H., Arakawa, A., Ozaki, Y., Asai, H., Kawai, M., Mizuno, K., Takahashi, S., et al. (2014) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.12324 · Cited by 16
“Recent findings suggested that BMP2 treatment in vitro mimicked the effects of carcinoma-associated mesenchymal stem cells (MSC) on cancer stem cells, while inhibiting BMP signaling in vitro and in vivo partly abrogated MSC-promoted tumor growth.(28) The data also suggests that MSC in the ovarian tumor microenvironmen…”
Backgroundde Oliveira-Lopes, A. F., Götze, M. M., Lopes-Neto, B. E., Guerreiro, D. D., Bustamante‐Filho, I. C., & Moura, A. A. (2024) · Veterinary and Comparative Oncology · doi:10.1111/vco.12996 · Cited by 15
Mesenchymal niches of bone marrow in cancer
Abarrategi, A., Mariñas‐Pardo, L., Mirones, I., Rincón, E., & García-Castro, J. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0706-x · Cited by 15
MicroRNA-155 and its exosomal form: Small pieces in the gastrointestinal cancers puzzle
Guo, J., Zhong, L., & Momeni, M. R. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09920-2 · Cited by 14
“Of the various types of stromal cells, a noteworthy cell type is the cancer-associated fibroblasts (CAFs), which have been subject to growing attention with respect to their origins in current years (McLean et al. 2011).”
BackgroundSingle-Cell Transcriptome Analysis Reveals Mesenchymal Stem Cells in Cavernous Hemangioma
Ji, F., Liu, Y., Shi, J., Liu, C., Fu, S., Wang, H., Ren, B., Mi, D., Gao, S., & Sun, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.916045 · Cited by 15
“, bone sarcomas, lipomas, or infantile hemangiomas), less is known about them (McLean et al., 2011) and their identities are still uncertain without a gene-expression signature of MSCs as a reference.”
BackgroundPieterse, Z., Sinha, D., & Kaur, P. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16908-4_5 · Cited by 14
MicroRNA MiR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog.
Xu, C., Xu, M., Tan, L., Yang, H., Permuth‐Wey, J., Kruk, P. A., Wenham, R. M., Nicosia, S. V., Lancaster, J. M., Sellers, T. A., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.a112.374611 · Cited by 14
The effects of adipose‐derived stem cells on CD133‐expressing bladder cancer cells
Maj, M., Kokocha, A., Bajek, A., & Drewa, T. A. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28436 · Cited by 13
“This effect was, at least in part, mediated through altered BMP signaling.(28) Furthermore, a signaling loop between an ovarian tumor cell‐ secreted Hedgehog and CA‐MSC‐derived BMP4 promoted chemotherapy resistance both in vitro and in vivo.”
BackgroundMultipotent Mesenchymal Stromal Cells: Possible Culprits in Solid Tumors?
Johann, P. D., & Müller, I. (2015) · Stem Cells International · doi:10.1155/2015/914632 · Cited by 13
Shin, K. K., Lee, A. L., Kim, J. Y., Lee, S. Y., Bae, Y. C., & Jung, J. S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.040 · Cited by 13
“Several recent studies showed that inflammatory cytokines or cancer-secreted factors can induce the modification of MSCs and potentiate MSC-induced tumor growth [47], and cancer cell-derived lysophosphatidic acid-induced angiogenesis [48,49].”
BackgroundGene methylation of human ovarian carcinoma stromal progenitor cells promotes tumorigenesis
Ho, C., Shih, D., Hsiao, C.-C., Huang, S., Chang, S.-F., & Cheng, W. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0722-7 · Cited by 13
“It is well known that DNA methylation is one of the epigenetic mechanisms regulating the expression of stemness genes [33, 34] and the in vitro promotion of tumorsphere growth of cancer-associated MSCs [23].”
BackgroundResultInfluentialMesenchymal stromal cell engagement in cancer cell epithelial to mesenchymal transition
Trivanović, D. I., Krstić, J., Jauković, A., Bugarski, D. S., & Santibanez, J. F. (2017) · Developmental Dynamics · doi:10.1002/dvdy.24583 · Cited by 12
“1 % of the total cells of tumor sample mass (McLean et al., 2011; Brennen et al., 2013).”
BackgroundInfluentialThe Emerging Role of GC-MSCs in the Gastric Cancer Microenvironment: From Tumor to Tumor Immunity
Pan, Z., Tian, Y., Niu, G., & Cao, C. (2019) · Stem Cells International · doi:10.1155/2019/8071842 · Cited by 12
“Surprisingly, they also proved that tumor-resident MSCs are derived from BM-MSCs, revealing that BMMSCs maybe the precursors of TA-MSCs.”
BackgroundInfluentialAn Orthotopic Mouse Model of Ovarian Cancer using Human Stroma to Promote Metastasis
Atiya, H. I., Orellana, T. J., Wield, A. M., Frisbie, L. G., & Coffman, L. G. (2021) · Journal of Visualized Experiments · doi:10.3791/62382 · Cited by 12
Tang, H., Fayomi, A. P., Bai, S., Gupta, N., Cascio, S., Yang, D., & Buckanovich, R. J. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.02.004 · Cited by 12
Self-citationAyyub, C., Banerjee, K. K., & Joti, P. (2015) · Developmental Biology · doi:10.1016/j.ydbio.2015.07.019 · Cited by 12
Lučić, I., Kurtović, M., Mlinarić, M., Piteša, N., Gašparović, A. Č., Sabol, M., & Milković, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310683 · Cited by 11
(In)Distinctive Role of Long Non-Coding RNAs in Common and Rare Ovarian Cancers
Sabol, M., Calleja‐Agius, J., Fiore, R. D., Suleiman, S., Özcan, S., Ward, M. P., & Ozretić, P. (2021) · Cancers · doi:10.3390/cancers13205040 · Cited by 11
Burch, S. A., & Lopez, C. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042003 · Cited by 10
“MSC cells have been seen to localize with breast carcinomas [58,59], and promote metastasis [58,60].”
BackgroundHuman lung cancer-derived mesenchymal stem cells promote tumor growth and immunosuppression
Gao, X., Ren, H., Zhang, Z., Cao, S., Zhang, B., Sun, Q., Melino, G., & Huang, H. (2024) · Biology Direct · doi:10.1186/s13062-024-00479-w · Cited by 10
“The results of the present study indicate that MSCs are commonly present in the tumors of human patients with lung cancer, which is consistent with previous reports that MSCs are present in those with many other types of cancer [25, 26].”
ResultRole of cancer-associated mesenchymal stem cells in the tumor microenvironment: A review
Wang, K., & Ding, D. (2022) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_138_22 · Cited by 10
“These CaMSCs highly expressed bone morphogenetic protein (BMP) proteins, especially BMP2, and could enhance the population of cancer stem cells (CSCs) and increase tumorigenesis [53].”
BackgroundThe role of hypoxic mesenchymal stem cells in tumor immunity
Tian, Y., Fang, J., Zeng, F., Chen, Y., Pei, Y., Gu, F., Ding, C., Niu, G., & Gu, B. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109172 · Cited by 10
Suda, Y., Neri, S., Hashimoto, H., Higuchi, Y., Ishibashi, M., Sugano, M., Masutomi, K., Tsuboi, M., Ochiai, A., & Ishii, G. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2171-y · Cited by 10
The Systems Biology of Bone Morphogenetic Proteins
Sampath, K. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-47507-3_2 · Cited by 10
Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells
Frerichs, L. M., Frerichs, B., Petzsch, P., Köhrer, K., Windolf, J., Bittersohl, B., Hoffmann, M. J., & Grotheer, V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1228185 · Cited by 9
“The proliferation-promoting effects of MSC on the cancer cells of other entities, e.g., ovarian, colorectal, and liver cancer, were already reported (80 – 82).”
Simão, V. A., Floriano, J. F., Cesário, R. C., Tonon, K. D. S., de Oliveira, L. R. C., Delella, F. K., Almeida, F. B. D. R., dos Santos, L. D., Seiva, F. R. F., Zuccari, D. A. P. D. C., et al. (2025) · Cells · doi:10.3390/cells14050374 · Cited by 9
“Consistent with this, McLean and colleagues [46] described carcinoma-associated MSCs (CA-MSCs) exhibiting phenotypic markers similar to ASCs within OC tissue.”
Wang, H., Ye, X., Xiao, H., Zhu, N., Wei, C., Sun, X., Wang, L., Wang, B., Yu, X., Lai, X., et al. (2019) · Stem Cells International · doi:10.1155/2019/4686132 · Cited by 9
“hematopoiesis and tumorigenesis through crosstalk with their target cells [35, 36].”
BackgroundTaylor, S. E., Chan, D., Yang, D., Bruno, T., Lieberman, R. W., Siddiqui, J., Soong, T. R., Coffman, L. G., & Buckanovich, R. J. (2022) · Cancers · doi:10.3390/cancers14092298 · Cited by 9
Self-citationMarín‐Aquino, L. A., Mora‐García, M. D. L., Moreno-Lafont, M. C., García‐Rocha, R., Montesinos, J. J., López‐Santiago, R., Sánchez‐Torres, L. E., Torres‐Pineda, D. B., Weiss‐Steider, B., Hernández‐Montes, J., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4010 · Cited by 9
A novel humanized immune stroma PDX cancer model for therapeutic studies
Yang, D., Beddows, I., Tang, H., Bai, S., Cascio, S., McGonigal, S. C., Johnson, B. K., Powers, J. J., Acharya, R., Bao, R., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04349-4 · Cited by 8
Self-citationBone morphogenetic protein signaling is a possible therapeutic target in gynecologic cancer
Fukuda, T., Suzuki, E., & Fukuda, R. (2022) · Cancer Science · doi:10.1111/cas.15682 · Cited by 8
Ma, C., Chen, Y., Wilkins, D. E., Chen, X. '., & Zhang, J. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s9-s3 · Cited by 8
“BMP4 [31,32]”
Zhang, T., Lee, W., Rui, Y., Cheng, T. Y., & Li, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt047.9 · Cited by 8
“Moreover, the interaction of MSCs with tumor cells to promote angiogenesis could also be found in human ovarian carcinoma cells and melanoma cancer cells [44,45].”
Tumor versus Stromal Cells in Culture—Survival of the Fittest?
Talasila, K. M., Brekkå, N., Mangseth, K., Stieber, D., Evensen, L., Røsland, G. V., Torsvik, A., Wagner, M., Niclou, S. P., Mahesparan, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081183 · Cited by 8
“The human cells derived from primary oligodendroglioma had the morphology of so-called mesenchymal stem cells (Figure 8a) that are often derived from primary tumor biopsies of various tissue types [19,20].”
BackgroundResultInfluentialCabarcas‐Petroski, S., Sun, L., Mathews, L., Thomas, S. B., Zhang, X., & Farrar, W. L. (2013) · Pancreas · doi:10.1097/mpa.0b013e318279d568 · Cited by 8
Gu, J., Wang, C., Xu, X., Zhao, L., Zhou, J., Bai, C., & Sun, Z. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2365 · Cited by 7
“Chemokines can promote stem cell formation of tumor cells (11,12), induce drug resistance (13), and promote angiogenesis (14) by upregulating the expression of epithelial mesenchymal transformation related genes such as ZEB-1, CXCR4 and Snail, etc.”
BackgroundSingle Mesenchymal Stromal Cell Migration Tracking into Glioblastoma Using Photoconvertible Vesicles
Sindeeva, O. A., Анатольевна, Д. П., Kozyreva, Z. V., Terentyeva, D. A., Gusliakova, О. I., Muslimov, A. R., & Sukhorukov, G. B. (2024) · Nanomaterials · doi:10.3390/nano14141215 · Cited by 7
“…in vitro or in vivo studies suggest that MSCs increase the number and tumorigenicity of cancer stem cells in various tumors, including human ovarian tumors [48], breast cancer [49], colorectal tumors [50], prostate cancer [51], Ewing’s sarcoma [52], and hepatocellular carcinoma [2], among others.”
BackgroundDecoding secret role of mesenchymal stem cells in regulating cancer stem cells and drug resistance
Panda, S. K., Robinson, N., & Desiderio, V. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189205 · Cited by 7
Update on Mesenchymal Stem Cells: A Crucial Player in Cancer Immunotherapy
Taeb, S., Rostamzadeh, D., Mafi, S., Mofatteh, M., Zarrabi, A., Hushmandi, K., Safari, A., Khodamoradi, E., & Najafi, M. (2022) · Current Molecular Medicine · doi:10.2174/1566524023666221226143814 · Cited by 7
Mesenchymal Stem Cells in Cancer: a New Link to Neutrophils
(2014) · Cancer Cell & Microenvironment · doi:10.14800/ccm.288 · Cited by 7
“For instance, MSCs have been suggested as the precursors of cancerassociated fibroblasts (CAFs) ([12]), which have prompting roles in tumor progression ([13-15]).”
BackgroundBMPs morph into new roles in ovarian cancer
McLean, K., & Buckanovich, R. J. (2013) · Cell Cycle · doi:10.4161/cc.23553 · Cited by 7
Self-citationMesenchymal stromal/stem cells in tumour initiation, progression and therapy
Garcia, G. L., Baruwal, R., Suresh, S., Britt, A. K., Li, A., Atiya, H. I., & Coffman, L. G. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00936-w · Cited by 6
“The effect of MSCs on cancer initiation has not been well studied, mainly because cancer initiation was long thought to occur independent of stromal influence, Therefore, studies on cancer initiation were focused on the cells of origin or cancer initiating cells (CICs, also known as CSCs).”
InfluentialSnyder, C. S., Repetto, T., Burkhard, K. M., Tuteja, A., & Mehta, G. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3730-2_14 · Cited by 6
Yang, X., Zheng, M., Ning, Y., Sun, J., Yu, Y., & Zhang, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04284-3 · Cited by 6
“Cancer-associated MSCs (CA-MSCs) can be isolated and identified in tumor tissue, and exhibit a unique gene expression profile from MSCs compared to that of healthy individuals [12].”
BackgroundRole of MSCs in Antitumor Drug Resistance
Naour, A. L., & Couderc, B. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803102-5.00013-6 · Cited by 6
Wang, K., Chang, Y., & Ding, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126746 · Cited by 5
“The presence of MSCs in the tumor microenvironment often leads to an increase in cancer cell division and growth, contributing to the expansion of the tumor [41,42].”
BackgroundEngineering colloidal systems for cell manipulation, delivery, and tracking
Sindeeva, O. A., Kozyreva, Z. V., Abdurashitov, A. S., & Sukhorukov, G. B. (2025) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2025.103462 · Cited by 5
Sarcinella, A., Villacis, J. S. G., & Brizzi, M. F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311462 · Cited by 5
“The CA-MSC-driven BMP dysregulation [181] and SDF-1/CXCR4 signaling [182] highlight the importance of the tumor stroma, but their impact on clinical chemoresistance remains underexplored.”
Jiang, Y., Gao, X. M., Zheng, X., Lü, Y., Zhang, M., Yan, W., Pan, W., Li, H., & Zhang, Y. (2024) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_540_23 · Cited by 5
Metadata
- Authors
- McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., & Buckanovich, R. J.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Buckanovich, Ronald J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-08-01
- Volume
- 121
- Issue
- 8
- Pages
- 3206-3219
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3148732
- OpenAlex
- W1970698543
- Cited by
- 380
- References
- 57
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 20 · 2023: 44 · 2022: 29 · 2021: 34 · 2020: 19 · 2019: 25 · 2018: 28 · 2017: 23 · 2016: 30 · 2015: 22 · 2014: 28 · 2013: 28 · 2012: 26
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- University of Michigan (48109)
- College of Pharmacy, University of Michigan
- U.S. Public Health Service (P01 093900)
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- ovarian carcinoma, mesenchymal stem cells, cancer stem cells, tumor microenvironment, BMP signaling, BMP-2, BMP4, BMP6, carcinogenesis, stem cell recruitment, multipotency
- MeSH terms
- Cell Differentiation, Cell Separation, Female, Humans, Models, Biological, Ovarian Neoplasms, Phenotype, Neoplastic Stem Cells, Signal Transduction, Gene Expression Regulation, Neoplastic, Bone Morphogenetic Proteins, Gene Expression Profiling, Cell Line, Tumor, Tumor Microenvironment, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.